Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis

被引:0
作者
Karen K. L. Chan
Michelle K. Y. Siu
Yu-xin Jiang
Jing-jing Wang
Yan Wang
Thomas H. Y. Leung
Stephanie S. Liu
Annie N. Y. Cheung
Hextan Y. S. Ngan
机构
[1] The University of Hong Kong,Department of Obstetrics and Gynaecology
[2] Queen Mary Hospital,Department of Pathology
[3] The University of Hong Kong,Department of Pathology
[4] Queen Mary Hospital,undefined
[5] The University of Hong Kong - Shenzhen Hospital,undefined
来源
BMC Cancer | / 17卷
关键词
Estrogen receptors; Ovarian cancer; Prognostic marker; Cell invasion and proliferation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 278 条
[1]  
Siegel R(2011)Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 212-236
[2]  
Ward E(2003)Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat Rev Cancer 3 502-516
[3]  
Brawley O(2012)Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer 19 R255-R279
[4]  
Jemal A(2002)Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research Gynecol Oncol 84 201-209
[5]  
Agarwal R(1996)Cloning of a novel receptor expressed in rat prostate and ovary Proc Natl Acad Sci U S A 93 5925-5930
[6]  
Kaye SB(1996)ER beta: identification and characterization of a novel human estrogen receptor FEBS Lett 392 49-53
[7]  
Modugno F(2010)A new class of estrogen receptor beta-selective activators Mol Interv 10 133-136
[8]  
Laskey R(2008)Estrogen receptor subtypes in ovarian cancer: a clinical correlation Obstet Gynecol 111 144-151
[9]  
Smith AL(2008)Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5′-untranslated region in human epithelial ovarian carcinoma Cancer Sci 99 2365-2372
[10]  
Andersen CL(2014)Targeting estrogen receptor subtypes (ERalpha and ERbeta) with selective ER modulators in ovarian cancer J Endocrinol 221 325-336